Laura Magnani

Laura Magnani

Auto-generated profile, based on publicly available information

Laura Magnani

Department of Haematology, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
MCMariasilvia Colantuoni
Mariasilvia Colantuoni
RHRaisa Jofra Hernandez
Raisa Jofra Hernandez
EPEmanuela Pettinato
Emanuela Pettinato
LBLuca Basso-Ricci
Luca Basso-Ricci
LMLaura Magnani
Laura Magnani
AMAlessandra Mortellaro
Alessandra Mortellaro
Dysregulation of the interleukin-1 (IL-1) pathway leads to immune diseases that can result in chronic tissue and organ inflammation. Although IL-1 blockade has shown promise in ameliorating these symptoms and improving patients’ quality of life, there is an urgent need for more effective, long-lasting treatments. We developed a lentivirus (LV)–mediated gene transfer strategy using transplanted autologous hematopoietic stem/progenitor cells (HSPCs) as a source of IL-1 receptor antagonist (IL-1RA) for systemic delivery to tissues and organs. Transplantation of mouse and human HSPCs transduced with an IL-1RA–encoding LV ensured stable IL-1RA production while maintaining the clonogenic and differentiation capacities of HSPCs in vivo. We examined the efficacy of cell-mediated IL-1RA delivery in three models of IL-1–dependent inflammation, for which treatment hindered neutrophil recruitment in an inducible model of gout, prevented systemic and multi-tissue inflammation in a genetic model of cryopyrin-associated periodic syndromes, and reduced disease severity in an experimental autoimmune encephalomyelitis model of multiple sclerosis. Our findings demonstrate HSPC-mediated IL-1RA delivery as a potential therapeutic modality that can be exploited to suppress tissue and organ inflammation in diverse immune-related diseases involving IL-1–driven inflammation.

1 January 2005 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
KSKatia Sparnacci
Katia Sparnacci
MLMichele Laus
Michele Laus
LTLuisa Tondelli
Luisa Tondelli
CBCinzia Bernardi
Cinzia Bernardi
LMLaura Magnani
Laura Magnani
ACAntonella Caputo
Antonella Caputo
Functional poly(methyl methacrylate) core–shell microspheres were prepared by dispersion polymerization. An appropriate selection of experimental parameters and in particular of the initiator and stabilizer amount and of the medium solvency power allowed a monodisperse sample as large as 600 nm to be prepared. To this purpose, low initiator concentration, high steric stabilizer amount and a low solvency power medium were employed. The microspheres present a core–shell structure in which the outer shell is constituted by the steric stabilizer which affords carboxylic groups able to interact with basic proteins, such as trypsin, whose adsorption is essentially driven by the carboxylic group density in the microsphere shell. Finally, fluorescent microspheres were prepared for biodistribution studies and shown to be readily taken up by the cells both in vitro and in vivo. These results suggest that these microspheres are promising delivery systems for the development of novel protein-based vaccines.

3 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ECE.F. Calderbank-May
E.F. Calderbank-May
HBH.P. Bastos
H.P. Bastos
LML. Magnani
L. Magnani
HFH. Foster
H. Foster
KSK. Sham
K. Sham
ELE. Laurenti
E. Laurenti
Commitment events to specific blood lineages arise from single hematopoietic stem cells (HSCs) and are influenced by stress, inflammation and disease. However, the understanding of how such events are regulated in human haematopoiesis is limited by the lack of tractable in vitro models. In this study, we introduce a novel Early Progenitor Differentiation (EPD) assay to study the initial lineage commitment of human 49f⁺ HSCs, in a system faithfully recapitulating cell states observed in vivo . Combining single cell -omics approaches and single-cell functional assays, we show that IL-33 acts directly on human 49f⁺ HSCs activating the MAPK pathway to enhance their commitment towards Megakaryocytic–Erythroid–Mast cell Progenitors and subsequently megakaryopoiesis. This occurs without affecting HSC self-renewal via accelerated establishment of chromatin programmes associated with Erythroid and Megakaryocyte and mast cells lineages. Our findings demonstrate the utility of the EPD model to identify molecular regulators of human HSC differentiation and uncover a new role of IL-33 in haematopoiesis.